JP2012525395A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525395A5
JP2012525395A5 JP2012508595A JP2012508595A JP2012525395A5 JP 2012525395 A5 JP2012525395 A5 JP 2012525395A5 JP 2012508595 A JP2012508595 A JP 2012508595A JP 2012508595 A JP2012508595 A JP 2012508595A JP 2012525395 A5 JP2012525395 A5 JP 2012525395A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyridinyl
triazin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012508595A
Other languages
English (en)
Japanese (ja)
Other versions
JP5697662B2 (ja
JP2012525395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032593 external-priority patent/WO2010126895A1/en
Publication of JP2012525395A publication Critical patent/JP2012525395A/ja
Publication of JP2012525395A5 publication Critical patent/JP2012525395A5/ja
Application granted granted Critical
Publication of JP5697662B2 publication Critical patent/JP5697662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012508595A 2009-04-28 2010-04-27 PI3キナ−ゼおよび/またはmTORの阻害薬 Active JP5697662B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17352009P 2009-04-28 2009-04-28
US61/173,520 2009-04-28
US25853209P 2009-11-05 2009-11-05
US61/258,532 2009-11-05
PCT/US2010/032593 WO2010126895A1 (en) 2009-04-28 2010-04-27 Inhibitors of pi3 kinase and / or mtor

Publications (3)

Publication Number Publication Date
JP2012525395A JP2012525395A (ja) 2012-10-22
JP2012525395A5 true JP2012525395A5 (enExample) 2013-06-13
JP5697662B2 JP5697662B2 (ja) 2015-04-08

Family

ID=42315845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508595A Active JP5697662B2 (ja) 2009-04-28 2010-04-27 PI3キナ−ゼおよび/またはmTORの阻害薬

Country Status (23)

Country Link
US (2) US8362241B2 (enExample)
EP (1) EP2424859B1 (enExample)
JP (1) JP5697662B2 (enExample)
KR (1) KR20120007540A (enExample)
CN (1) CN102548984B (enExample)
AR (1) AR076486A1 (enExample)
AU (1) AU2010241723B2 (enExample)
BR (1) BRPI1015262A2 (enExample)
CA (1) CA2758986C (enExample)
CL (1) CL2011002691A1 (enExample)
CO (1) CO6440596A2 (enExample)
CR (1) CR20110634A (enExample)
EA (1) EA019700B1 (enExample)
IL (1) IL215731A0 (enExample)
MA (1) MA34207B1 (enExample)
MX (1) MX2011011335A (enExample)
NZ (1) NZ595572A (enExample)
PE (1) PE20121159A1 (enExample)
SG (1) SG175364A1 (enExample)
TW (1) TW201103902A (enExample)
UY (1) UY32582A (enExample)
WO (1) WO2010126895A1 (enExample)
ZA (1) ZA201108101B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2474147T3 (es) * 2008-05-30 2014-07-08 Amgen, Inc Inhibidores de PI3 cinasa
WO2010108074A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Inhibitors of pi3 kinase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
FR2958290B1 (fr) 2010-03-30 2012-10-19 Sanofi Aventis Procede de preparation de derives de sulfonamido-benzofurane
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
HUP1000330A2 (en) 2010-06-18 2011-12-28 Sanofi Sa Process for the preparation of dronedarone and the novel intermediates
US9216981B2 (en) 2010-12-02 2015-12-22 Medpacto, Inc. Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient
US9284270B2 (en) 2011-02-14 2016-03-15 The Governers Of The University Of Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
AU2012225382B2 (en) * 2011-03-09 2016-10-27 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
HUP1100165A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Process for preparation of dronedarone by n-butylation
HUP1100167A2 (en) 2011-03-29 2012-11-28 Sanofi Sa Process for preparation of dronedarone by mesylation
HUE059230T2 (hu) * 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
CN103974954B (zh) * 2011-11-14 2016-08-24 北京赛林泰医药技术有限公司 调节激酶的化合物、含有它们的组合物及其用途
FR2983198B1 (fr) 2011-11-29 2013-11-15 Sanofi Sa Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP2617718A1 (en) 2012-01-20 2013-07-24 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9249119B2 (en) * 2012-02-14 2016-02-02 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
WO2013178337A1 (en) 2012-05-31 2013-12-05 Sanofi Process for preparation of dronedarone by grignard reaction
HK1206331A1 (en) * 2012-08-09 2016-01-08 Neuropore Therapies, Inc. Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN104418849B (zh) * 2013-09-02 2020-04-21 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2015048318A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
AU2014346354A1 (en) 2013-11-11 2016-05-26 Amgen Inc. Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
RU2760373C2 (ru) 2015-09-18 2021-11-24 Какен Фармасьютикал Ко., Лтд. Биарильное производное и содержащее его лекарственное средство
KR102031033B1 (ko) 2016-02-03 2019-11-18 삼진제약주식회사 라프 키나제 및 혈관내피성장인자 수용체(vegfr2)를 저해하는 피리딘 유도체, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이의 용도
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018071794A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
JP6469272B2 (ja) * 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
MX2019011002A (es) 2017-03-14 2019-12-16 Basf Se Azinas herbicidas.
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
CA3080578A1 (en) 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
BR112020018094A2 (pt) * 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP4234547A3 (en) 2018-05-14 2023-11-01 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
KR20250171404A (ko) 2018-08-31 2025-12-08 암젠 인크 Mdm2 억제제의 제조 방법
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3898589A2 (de) * 2018-12-21 2021-10-27 Saltigo GmbH Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
KR20220011670A (ko) 2019-05-21 2022-01-28 암젠 인크 고체 상태 형태
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
KR102852061B1 (ko) * 2020-03-09 2025-08-27 삼성중공업 주식회사 선박용 볼라드
EP4169914A4 (en) * 2020-06-23 2024-07-24 Shenzhen Forward Pharmaceuticals Co., Ltd. SALT OF A COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SALT
CN116283467B (zh) * 2023-01-18 2024-06-11 四川大学 一种合成二芳基烷基甲烷的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
CA2394639A1 (en) 1999-12-15 2001-06-21 Danny Peter Claude Mcgee Salicylamides as serine protease and factor xa inhibitors
NZ521245A (en) 2000-03-17 2004-04-30 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
US7435823B2 (en) 2004-01-23 2008-10-14 Amgen Inc. Compounds and methods of use
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
ES2395196T3 (es) 2005-03-11 2013-02-11 Zenyaku Kogyo Kabushikikaisha Agente inmunosupresor que comprende un compuesto heterocíclico como ingrediente activo
WO2006123165A2 (en) 2005-05-19 2006-11-23 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
WO2007011721A1 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007087276A1 (en) 2006-01-23 2007-08-02 Amgen Inc. Aurora kinase modulators and method of use
JP2009525978A (ja) * 2006-02-06 2009-07-16 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
ES2365258T3 (es) * 2006-06-26 2011-09-27 Ucb Pharma S.A. Derivados de tiazol condensados como inhibidores de quinasa.
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101595103A (zh) 2006-09-14 2009-12-02 阿斯利康(瑞典)有限公司 嘧啶衍生物
WO2008032028A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090325954A1 (en) 2006-09-14 2009-12-31 Sam Butterworth 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP2064203A1 (en) 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EA200901065A1 (ru) 2007-02-06 2010-02-26 Новартис Аг Ингибиторы pi 3-киназы и способы их применения
WO2009007751A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AR067478A1 (es) 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
ATE554075T1 (de) 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
EA201000104A1 (ru) 2007-07-26 2010-08-30 Новартис Аг Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
WO2010014939A1 (en) 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
TW201022208A (en) 2008-10-30 2010-06-16 Herbalscience Group Llc Tryptase enzyme inhibiting aminopyridines
AU2009309019B2 (en) 2008-10-31 2014-11-13 Merck Sharp & Dohme Llc P2X3, receptor antagonists for treatment of pain
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
BRPI1008376B1 (pt) 2009-02-10 2021-08-31 Janssen Pharmaceutica Nv Quinazolinonas como inibidores de prolil hidroxilase
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド mTORキナーゼ阻害剤としてのインドール/ベンゾイミダゾール化合物
EP2403847B1 (en) 2009-03-06 2016-03-02 UCB Biopharma SPRL Triazine derivatives as kinase inhibitors
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2012529512A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用

Similar Documents

Publication Publication Date Title
JP2012525395A5 (enExample)
US12522605B2 (en) FGFR inhibitors and methods of use thereof
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
JP5650735B2 (ja) タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体
AU2019323035B2 (en) Pyrazine compounds and uses thereof
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
CA2845578C (en) Pyrimidine pde10 inhibitors
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
KR20200131246A (ko) 키나제 억제제로서의 헤테로시클릭 화합물
JP2014521711A5 (enExample)
EA019506B1 (ru) Конденсированные гетероциклические производные и их применение
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
RU2012136643A (ru) [5,6]- гетероциклическое соединение
RU2017112518A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2023021316A (ja) ピリジンアミン-ピリドンおよびピリミジンアミン-ピリドン化合物
WO2024076672A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
WO2020100027A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
JP2019535664A5 (enExample)
AU2014211856A1 (en) Substituted 2-aminopyridine protein kinase inhibitor
JP2017526720A (ja) キナーゼ阻害剤としての化合物および組成物
JP2020504139A5 (enExample)
CN115557933B (zh) 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用
JP2023021276A (ja) ピリジルピリドン化合物
JP2023021277A (ja) アザインドリルピリドンおよびジアザインドリルピリドン化合物
AU2021218497A1 (en) Quinolyl phosphine oxide compound, and composition and application thereof